{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:21:15Z","timestamp":1790724075986,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008725","name":"Maj Institute of Pharmacology Polish Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.neuropharm.2024.109865","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T21:48:16Z","timestamp":1707515296000},"page":"109865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy"],"prefix":"10.1016","volume":"249","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-4224","authenticated-orcid":false,"given":"Joanna","family":"Kula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-6447","authenticated-orcid":false,"given":"Katarzyna Z.","family":"Kuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.109865_bib1","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81453","article-title":"A prebiotic diet modulates microglial states and motor deficits in \u03b1-synuclein overexpressing mice","volume":"11","author":"Abdel-Haq","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib2","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1038\/s41467-020-17876-0","article-title":"A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders","volume":"11","author":"Agarwal","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/nu14020380","article-title":"Are We what We Eat? Impact of diet on the gut\u2013brain Axis in Parkinson's disease","volume":"14","author":"Alfonsetti","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2024.109865_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00175","article-title":"Lipids at the crossroad of \u03b1-synuclein function and dysfunction: biological and pathological implications","volume":"13","author":"Alza","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-021-02067-6","article-title":"SCD1, autophagy and cancer: implications for therapy","volume":"40","author":"Ascenzi","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.bmcl.2011.01.113","article-title":"N-Benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors","volume":"21","author":"Atkinson","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"11","key":"10.1016\/j.neuropharm.2024.109865_bib7","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1194\/jlr.M200189-JLR200","article-title":"Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia","volume":"43","author":"Attie","year":"2002","journal-title":"JLR (J. Lipid Res.)"},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib8","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.3390\/ijms24065531","article-title":"Role of stearoyl-CoA desaturase 1 in cardiovascular physiology","volume":"24","author":"Balatskyi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/hsz-2016-0277","article-title":"Control of membrane fluidity: the OLE pathway in focus","volume":"398","author":"Ballweg","year":"2017","journal-title":"Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41467-020-14528-1","article-title":"Regulation of lipid saturation without sensing membrane fluidity","volume":"11","author":"Ballweg","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.109865_bib11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/mds.29172","article-title":"Gray matter volume loss in proposed <scp>Brain\u2010First<\/scp> and <scp>Body\u2010First<\/scp> Parkinson's disease subtypes","volume":"37","author":"Banwinkler","year":"2022","journal-title":"Mov. Disord."},{"issue":"13","key":"10.1016\/j.neuropharm.2024.109865_bib12","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1097\/00001756-199909090-00019","article-title":"Neural expression profile of \u03b1-synuclein in developing human cortex","volume":"10","author":"Bayer","year":"1999","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.109865_bib13","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3233\/JPD-212733","article-title":"Vagus nerve and stomach synucleinopathy in Parkinson's disease, incidental Lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d hypothesis","volume":"11","author":"Beach","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109865_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01399","article-title":"Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles","volume":"13","author":"Bernal-Conde","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109865_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.759571","article-title":"Functions of intracellular alpha-synuclein in microglia: implications for Parkinson's disease risk","volume":"15","author":"Booms","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","article-title":"The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models","volume":"130","author":"Borghammer","year":"2023","journal-title":"J. Neural. Transm."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","article-title":"Gastric \u03b1-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology","volume":"396","author":"Braak","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.109865_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00401-007-0244-3","article-title":"Development of \u03b1-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease","volume":"114","author":"Braak","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.109865_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JPD-150642","article-title":"The synaptic function of \u03b1-synuclein","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J. Parkinsons Dis."},{"issue":"40","key":"10.1016\/j.neuropharm.2024.109865_bib20","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1416598111","article-title":"\u03b1-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation","volume":"111","author":"Burr\u00e9","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.109865_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2148-11-132","article-title":"The evolutionary history of the stearoyl-CoA desaturase gene family in vertebrates","volume":"11","author":"Castro","year":"2011","journal-title":"BMC Evol. Biol."},{"issue":"6161","key":"10.1016\/j.neuropharm.2024.109865_bib23","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.1245296","article-title":"Identification and rescue of \u03b1-synuclein toxicity in Parkinson patient\u2013derived neurons","volume":"342","author":"Chung","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib24","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1038\/s41467-022-33252-6","article-title":"Small soluble \u03b1-synuclein aggregates are the toxic species in Parkinson's disease","volume":"13","author":"Emin","year":"2022","journal-title":"Nat. Commun."},{"issue":"679","key":"10.1016\/j.neuropharm.2024.109865_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq6288","article-title":"Targeting de novo lipid synthesis induces lipotoxicity and impairs DNA damage repair in glioblastoma mouse models","volume":"15","author":"Eyme","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41531-022-00335-6","article-title":"Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy","volume":"8","author":"Fanning","year":"2022","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"5","key":"10.1016\/j.neuropharm.2024.109865_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","article-title":"Lipidomic analysis of \u03b1-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment","volume":"73","author":"Fanning","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuropharm.2024.109865_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00742","article-title":"Lipid droplets in neurodegenerative disorders","volume":"14","author":"Farmer","year":"2020","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40478-022-01469-7","article-title":"Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain","volume":"10","author":"Fu","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.109865_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JPD-171103","article-title":"The role of lipids interacting with \u03b1-synuclein in the pathogenesis of Parkinson's disease","volume":"7","author":"Galvagnion","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12883-018-1034-3","article-title":"A survey of subjective constipation in Parkinson's disease patients in shanghai and literature review","volume":"18","author":"Gan","year":"2018","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167714","article-title":"Functional and pathological effects of \u03b1-synuclein on synaptic SNARE complexes","volume":"435","author":"Gao","year":"2023","journal-title":"J. Mol. Biol."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.109865_bib33","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41416-020-0827-5","article-title":"Stearoyl-CoA-desaturase-1 regulates gastric cancer stem-like properties and promotes tumour metastasis via Hippo\/YAP pathway","volume":"122","author":"Gao","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting \u03b1 -synuclein for Parkinson's disease","volume":"74","author":"Grosso Jasutkar","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib36","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41467-022-29506-y","article-title":"Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer's disease mouse model","volume":"13","author":"Hamilton","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2024.109865_bib37","series-title":"Biochemistry and Health Benefits of Fatty Acids","article-title":"Fatty acids: from membrane ingredients to signaling molecules","author":"Hashimoto","year":"2018"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","article-title":"Initiation and propagation of \u03b1-synuclein aggregation in the nervous system","volume":"15","author":"Hijaz","year":"2020","journal-title":"Mol. Neurodegener."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.109865_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mds.26942","article-title":"Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome","volume":"32","author":"Hill\u2010Burns","year":"2017","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.109865_bib40","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/brain\/awaa238","article-title":"Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study","volume":"143","author":"Horsager","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1471-4159.1998.71010338.x","article-title":"Expression pattern of synucleins (Non-A\u03b2 component of Alzheimer's disease amyloid precursor protein\/\u03b1-synuclein) during murine brain development","volume":"71","author":"Hsu","year":"2002","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib42","article-title":"Stearoyl-CoA desaturase 5 (SCD5), a \u0394-9 fatty acyl desaturase in search of a function","volume":"1866","author":"Igal","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"41","key":"10.1016\/j.neuropharm.2024.109865_bib43","doi-asserted-by":"crossref","first-page":"20760","DOI":"10.1073\/pnas.1903216116","article-title":"Cell models of lipid-rich \u03b1-synuclein aggregation validate known modifiers of \u03b1-synuclein biology and identify stearoyl-CoA desaturase","volume":"116","author":"Imberdis","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2024.109865_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.863907","article-title":"Functions of stress-induced lipid droplets in the nervous system","volume":"10","author":"Islimye","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-022-00289-y","article-title":"Pathophysiological significance of increased \u03b1-synuclein deposition in sympathetic nerves in Parkinson's disease: a post-mortem observational study","volume":"11","author":"Isonaka","year":"2022","journal-title":"Transl. Neurodegener."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.109865_bib46","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4103\/1673-5374.382231","article-title":"Pathological and physiological functional cross-talks of \u03b1-synuclein and tau in the central nervous system","volume":"19","author":"Jin","year":"2024","journal-title":"Neural Regeneration Research"},{"issue":"25","key":"10.1016\/j.neuropharm.2024.109865_bib47","doi-asserted-by":"crossref","first-page":"14755","DOI":"10.1016\/S0021-9258(18)63763-9","article-title":"Differentiation-induced gene expression in 3T3-L1 preadipocytes","volume":"264","author":"Kaestner","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrn2809","article-title":"Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast?","volume":"11","author":"Khurana","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"25","key":"10.1016\/j.neuropharm.2024.109865_bib49","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1007\/s00216-014-8020-4","article-title":"Fatty acid desaturation index in human plasma: comparison of different analytical methodologies for the evaluation of diet effects","volume":"406","author":"Klawitter","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"issue":"15","key":"10.1016\/j.neuropharm.2024.109865_bib50","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1016\/j.bmcl.2009.06.017","article-title":"Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors","volume":"19","author":"Koltun","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0005-2760(96)00145-2","article-title":"Differential expression of hepatic stearoyl-CoA desaturase gene 1 in male and female mice","volume":"1304","author":"Lee","year":"1996","journal-title":"Biochim. Biophys. Acta Lipids Lipid. Metabol."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s42485-022-00088-z","article-title":"\u03b1-synuclein enfolds tyrosine hydroxylase and dopamine \u00df-hydroxylase, potentially reducing dopamine and norepinephrine synthesis","volume":"13","author":"Lehrer","year":"2022","journal-title":"J. Protein Proteonomics"},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib53","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/2767-9764.CRC-23-0030","article-title":"Targeting fatty acid reprogramming suppresses CARM1-expressing ovarian cancer","volume":"3","author":"Lombardi","year":"2023","journal-title":"Cancer Research Communications"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ane.12247","article-title":"Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review","volume":"130","author":"Malek","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib55","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1021\/acschemneuro.8b00383","article-title":"Alpha-synuclein in peripheral tissues in Parkinson's disease","volume":"10","author":"Ma","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib56","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41467-021-21027-4","article-title":"The docking of synaptic vesicles on the presynaptic membrane induced by \u03b1-synuclein is modulated by lipid composition","volume":"12","author":"Man","year":"2021","journal-title":"Nat. Commun."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2024.109865_bib57","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1080\/10715762.2016.1231403","article-title":"Fatty acid-related modulations of membrane fluidity in cells: detection and implications","volume":"50","author":"Maulucci","year":"2016","journal-title":"Free Radic. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson's disease \u2013 lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.109865_bib59","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/jid.2013.89","article-title":"Pharmacological inhibition of stearoyl CoA desaturase in the skin induces atrophy of the sebaceous glands","volume":"133","author":"Meingassner","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/biomedicines11020541","article-title":"The role of \u03b1-synuclein in the regulation of serotonin system: physiological and pathological features","volume":"11","author":"Miquel-Rio","year":"2023","journal-title":"Biomedicines"},{"issue":"36","key":"10.1016\/j.neuropharm.2024.109865_bib61","doi-asserted-by":"crossref","first-page":"33904","DOI":"10.1074\/jbc.M304724200","article-title":"Identification and characterization of murine SCD4, a novel heart-specific stearoyl-CoA desaturase isoform regulated by leptin and dietary factors","volume":"278","author":"Miyazaki","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.109865_bib62","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.3390\/ijms22126277","article-title":"Recent insights into the interplay of alpha-synuclein and sphingolipid signaling in Parkinson's disease","volume":"22","author":"Motyl","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.109865_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183536","article-title":"Interactions of \u03b1-synuclein oligomers with lipid membranes","volume":"1863","author":"Musteikyt\u0117","year":"2021","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib64","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2007.04.108","article-title":"Expression of \u03b1-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage","volume":"358","author":"Nakai","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.109865_bib65","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0166-21.2021","article-title":"SCD inhibition protects from \u03b1-synuclein-induced neurotoxicity but is toxic to early neuron cultures","volume":"8","author":"Nicholatos","year":"2021","journal-title":"Eneuro"},{"issue":"9","key":"10.1016\/j.neuropharm.2024.109865_bib66","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-2275(20)33401-5","article-title":"Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol","volume":"40","author":"Ntambi","year":"1999","journal-title":"JLR (J. Lipid Res.)"},{"key":"10.1016\/j.neuropharm.2024.109865_bib67","article-title":"A brain-penetrant stearoyl-CoA desaturase inhibitor reverses \u03b1-synuclein toxicity","author":"Nuber","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.25920","article-title":"A stearoyl\u2013coenzyme A desaturase inhibitor prevents multiple Parkinson disease phenotypes in <scp>\u03b1<\/scp> \u2010synuclein mice","volume":"89","author":"Nuber","year":"2021","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib69","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2018.09.014","article-title":"Abrogating native \u03b1-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson's disease","volume":"100","author":"Nuber","year":"2018","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neuropharm.2024.109865_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd7459","article-title":"Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer","volume":"7","author":"Oatman","year":"2021","journal-title":"Sci. Adv."},{"issue":"14","key":"10.1016\/j.neuropharm.2024.109865_bib71","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1021\/jm200319u","article-title":"Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia","volume":"54","author":"Oballa","year":"2011","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.109865_bib72","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/glia.23671","article-title":"Glial \u03b1\u2010synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo","volume":"67","author":"Olsen","year":"2019","journal-title":"Glia"},{"issue":"22","key":"10.1016\/j.neuropharm.2024.109865_bib73","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.3390\/ijms21228619","article-title":"Stearoyl-CoA desaturase-2 in murine development, metabolism, and disease","volume":"21","author":"O'Neill","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2024.109865_bib74","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2147\/JIR.S347784","article-title":"SCD1-Fatty acid desaturase inhibitor MF-438 alleviates latent inflammation induced by preservative-free prostaglandin analog eye drops","volume":"15","author":"Pacwa","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.neuropharm.2024.109865_bib75","series-title":"StatPearls [Internet]","article-title":"Physiology. Synuclein","author":"Patel","year":"2023"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib76","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1152\/ajpendo.90897.2008","article-title":"Biochemical and physiological function of stearoyl-CoA desaturase","volume":"297","author":"Paton","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41531-018-0042-8","article-title":"Management of constipation in patients with Parkinson's disease","volume":"4","author":"Pedrosa Carrasco","year":"2018","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/cells9010140","article-title":"Sterculic acid: the mechanisms of action beyond stearoyl-CoA desaturase inhibition and therapeutic opportunities in human diseases","volume":"9","author":"Pel\u00e1ez","year":"2020","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.neuropharm.2024.109865_bib79","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/biom11101435","article-title":"Sequential dynamics of stearoyl-CoA desaturase-1(SCD1)\/ligand binding and unbinding mechanism: a computational study","volume":"11","author":"Petroff","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41531-023-00618-6","article-title":"Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson's disease","volume":"10","author":"Prymaczok","year":"2024","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"7","key":"10.1016\/j.neuropharm.2024.109865_bib81","article-title":"Lipid droplets in the nervous system","volume":"220","author":"Ralhan","year":"2021","journal-title":"JCB (J. Cell Biol.)"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","article-title":"Dynamic physiological \u03b1-synuclein S129 phosphorylation is driven by neuronal activity","volume":"9","author":"Ramalingam","year":"2023","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"9","key":"10.1016\/j.neuropharm.2024.109865_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162047","article-title":"Stearoyl-CoA desaturase 1 is a key determinant of membrane lipid composition in 3T3-L1 adipocytes","volume":"11","author":"Rodriguez-Cuenca","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neuropharm.2024.109865_bib84","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3390\/cells10092452","article-title":"Alpha-synuclein and lipids: the elephant in the room?","volume":"10","author":"Sarchione","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib85","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/mds.25020","article-title":"Is alpha\u2010synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases","volume":"27","author":"Shannon","year":"2012","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib86","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1096\/fj.03-1112rev","article-title":"Does \u03b1\u2010synuclein modulate dopaminergic synaptic content and tone at the synapse?","volume":"18","author":"Sidhu","year":"2004","journal-title":"Faseb. J."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2024.109865_bib87","first-page":"1","article-title":"\u03b1-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease","volume":"565","author":"Sidhu","year":"2004","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.109865_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039787","article-title":"StearoylCoA desaturase-5: a novel regulator of neuronal cell proliferation and differentiation","volume":"7","author":"Sinner","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neuropharm.2024.109865_bib89","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/NEN.0b013e3181b66f1b","article-title":"Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression","volume":"68","author":"Song","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109865_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115586","article-title":"SCD1 is the critical signaling hub to mediate metabolic diseases: mechanism and the development of its inhibitors","volume":"170","author":"Sun","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089327","article-title":"Differential expression of alpha-synuclein in hippocampal neurons","volume":"9","author":"Taguchi","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.109865_bib92","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s12035-021-02695-1","article-title":"Non-clinical Pharmacology of YTX-7739: a clinical stage stearoyl-CoA desaturase inhibitor being developed for Parkinson's disease","volume":"59","author":"Tardiff","year":"2022","journal-title":"Mol. Neurobiol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2024.109865_bib93","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainres.2003.10.072","article-title":"The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain","volume":"1004","author":"Totterdell","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109865_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00010","article-title":"Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease","volume":"11","author":"Tracey","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.109865_bib95","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/cancers11070948","article-title":"Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer","volume":"11","author":"Tracz-Gaszewska","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/biom12010040","article-title":"Lipotoxicity downstream of \u03b1-synuclein imbalance: a relevant pathomechanism in synucleinopathies?","volume":"12","author":"Tripathi","year":"2021","journal-title":"Biomolecules"},{"issue":"S7","key":"10.1016\/j.neuropharm.2024.109865_bib97","doi-asserted-by":"crossref","first-page":"vii18","DOI":"10.1007\/s00415-004-1706-3","article-title":"Life style risks of Parkinson?s disease: association between decreased water intake and constipation","volume":"251","author":"Ueki","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109865_bib98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chemphyslip.2015.08.018","article-title":"Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors","volume":"197","author":"Uto","year":"2016","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.neuropharm.2024.109865_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105599","article-title":"Animal models of brain-first and body-first Parkinson's disease","volume":"163","author":"Van Den Berge","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2024.109865_bib100","article-title":"Phase I single (SAD) and multiple ascending dose (MAD) studies evaluating the safety, tolerability pharmacokinetics (PK) and pharmacodynamics (PD) of YTX-7739, a novel brain penetrant small molecule SCD inhibitor, in healthy subjects","volume":"1\u201398","author":"Verma","year":"2021","journal-title":"The Journal Of Prevention of Alzheimer\u2019s Disease (POSTERS 14th Conference Clinical Trials Alzheimer\u2019s Disease)"},{"issue":"11","key":"10.1016\/j.neuropharm.2024.109865_bib101","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-synuclein aggregation pathway in Parkinson's disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.neuropharm.2024.109865_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.11.028","article-title":"Inhibiting stearoyl-CoA desaturase ameliorates \u03b1-synuclein cytotoxicity","volume":"25","author":"Vincent","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib103","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13578-022-00828-0","article-title":"Lipid metabolism and storage in neuroglia: role in brain development and neurodegenerative diseases","volume":"12","author":"Yang","year":"2022","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.109865_bib104","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1006\/geno.2000.6429","article-title":"Scd3\u2014a novel gene of the stearoyl-CoA desaturase family with restricted expression in skin","volume":"71","author":"Zheng","year":"2001","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41531-023-00556-3","article-title":"Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease","volume":"9","author":"Zhou","year":"2023","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.109865_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108601","article-title":"Stearoyl-CoA desaturase-mediated monounsaturated fatty acid availability supports humoral immunity","volume":"34","author":"Zhou","year":"2021","journal-title":"Cell Rep."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:26:51Z","timestamp":1758439611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":105,"alternative-id":["S0028390824000327"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109865","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109865"}}